Oncopartners and IBPC (Instituto Brasileiro de Pesquisa em Câncer) have created a new strategy for enhancing global clinical oncology research by providing sponsors with well-controlled access to Brazil’s extensive patient population.  Eighty percent of Brazil’s 190 million citizens are served by the public healthcare system.  The country’s leading oncologists, highly motivated to participate in research which offers access to treatments and compounds otherwise unavailable through the public system’s formulary, formed IBPC.  Based in Princeton, NJ and São Paulo, Brazil, Oncopartners has made significant investments in assembling a team of international industry veterans supported by a customized IT infrastructure, robust SOPs, and active participation by leading oncologists throughout Brazil.  As exclusive partners with the premier network of public hospitals in Brazil, we are confident that our services and expertise will enable you to significantly increase the enrollment rate for Phase II and III studies and will ensure that data from the Brazilian sites is of the highest quality.  We work with our pharma, biotech, and CRO clients to identify the best solutions for their specific needs.

Oncopartners was created in response to the growing need for high-performing oncology investigative sites and to complement IBPC’s mission to provide expanded treatment options for oncologists and patients in Brazil’s public healthcare system.  The rapid expansion of international oncology clinical trials has far exceeded the capacity of leading research centers in Europe and North America which has resulted in slower patient accrual, longer timelines and escalating study costs per patient.  The expertise of our staff, combined with our international infrastructure, enables Oncopartners to leverage our relationships with IBPC and leading private hospitals in Brazil to offer our clients compelling solutions to their enrollment challenges.